Adoptive T cell therapy for solid tumors: current landscape and future challenges

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: March 14, 2024

Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, (TCR) gene-modified cells, with tumor-infiltrating (TILs). The outstanding results CAR-T in some hematologic malignancies have launched investigation ACT patients refractory solid malignancies. However, certain characteristics tumors, such as their antigenic heterogeneity immunosuppressive microenvironment, hamper efficacy antigen-targeted treatments. Other modalities, TIL emerged promising new strategies. has shown safety immunogenic cancers, mainly advanced melanoma, an exciting rationale for its combination checkpoint inhibitors. implementation clinical practice is hindered by several biological, logistic, economic challenges. In this review, we aim summarize current knowledge, available results, potential areas future research regarding use tumors

Language: Английский

---

Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(6), P. 709 - 709

Published: May 24, 2024

Of all the numerous nanosized extracellular vesicles released by a cell, endosomal-originated exosomes are increasingly recognized as potential therapeutics, owing to their inherent stability, low immunogenicity, and targeted delivery capabilities. This review critically evaluates transformative of exosome-based modalities across pharmaceutical precision medicine landscapes. Because precise biomolecular cargo delivery, posited ideal candidates in drug enhancing regenerative strategies, advancing diagnostic technologies. Despite significant market growth projections exosome therapy, its utilization is encumbered substantial scientific regulatory challenges. These include lack universally accepted protocols for isolation complexities associated with navigating environment, particularly guidelines set forth U.S. Food Drug Administration (FDA). presents comprehensive overview current research trajectories aimed at addressing these impediments discusses prospective advancements that could substantiate clinical translation exosomal therapies. By providing analysis both capabilities hurdles therapeutic applications, this article aims inform direct future paradigms, thereby fostering integration systems into mainstream practice.

Language: Английский

---

Environmental pollutants and exosomes: A new paradigm in environmental health and disease

The Science of The Total Environment, Journal Year: 2024, Volume and Issue: 925, P. 171774 - 171774

Published: March 18, 2024

Language: Английский

---

Biomimetic Lung-Targeting Nanoparticles with Antioxidative and Nrf2 Activating Properties for Treating Ischemia/Reperfusion-Induced Acute Lung Injury

Nano Letters, Journal Year: 2024, Volume and Issue: 24(7), P. 2131 - 2141

Published: Jan. 16, 2024

Ischemia/reperfusion (IR)-induced acute lung injury (ALI) has a high mortality rate. Reactive oxygen species (ROS) play crucial role in causing cellular damage and death IR-induced ALI. In this work, we developed biomimetic lung-targeting nanoparticle (PC@MB) as an antioxidative protector for treating PC@MBs showed excellent ROS scavenging Nrf2 activation properties, along with function through autologous cell membrane coating. The exhibited impressive pulmonary protective via redox homeostasis recovery heme oxygenase-1 activation. could maintain viability by effectively the intracellular restoring equilibrium lesion. IR mouse model, preferentially accumulated distinctly repaired pneumonic damage. Our strategy potential to offer promising therapeutic paradigm ALI incorporation of different mechanisms.

Language: Английский

---

Exosomes as targeted diagnostic biomarkers: Recent studies and trends

Life Sciences, Journal Year: 2024, Volume and Issue: 354, P. 122985 - 122985

Published: Aug. 14, 2024

Language: Английский

---

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Language: Английский

---

Exosome isolation and characterization for advanced diagnostic and therapeutic applications

Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101613 - 101613

Published: Feb. 25, 2025

Language: Английский

---

Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)

Published: March 18, 2025

Language: Английский

---

A carboxymethyl chitosan/oxidized hyaluronic acid composite hydrogel dressing loading with stem cell exosome for chronic inflammation wounds healing

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 257, P. 128534 - 128534

Published: Dec. 3, 2023

Language: Английский

---

Intracellularly Synthesized Artificial Exosome Treats Acute Lung Injury

ACS Nano, Journal Year: 2024, Volume and Issue: 18(32), P. 21009 - 21023

Published: Aug. 1, 2024

Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), induce high morbidity mortality rates, which challenge the present approaches for treatment of ALI/ARDS. The clinically used photosensitizer verteporfin (VER) exhibits great potential in (ALI/ARDS) by regulating macrophage polarization reducing inflammation. Nevertheless, hydrophobic characteristics, nonspecificity, constrained bioavailability hinder therapeutic efficacy. In this work, we developed a type VER-cored artificial exosome (EVM), was produced using mesoporous silica nanoparticles (MSNs) to load VER, followed exocytosis internalized VER-MSNs from mouse bone marrow-derived mesenchymal stem cells (mBMSCs) without further modification. Both vitro vivo assessments confirmed powerful anti-inflammation induced EVM. EVM also showed significant higher accumulation inflammatory lungs compared with healthy ones, beneficial improved pulmonary function, attenuated injury, reduced ALI mice levels biocompatibility, exhibiting 5-fold survival rate than control. This emitted near-infrared light presence laser activation, endowed trackable ability both vivo. Our work photosensitizer-loaded membrane integrity traceability. To best our knowledge, kind intracellularly synthesized ALI/ARDS therapy.

Language: Английский

---